Introduction
============

Induced pluripotent stem cells (iPSCs) are derived from somatic cells by transfecting two pluripotent transcription factors, Oct4 (O) and Sox2 (S), and two proto-oncogenes, c-Myc (M) and Klf4 (K). These four transcription factors globally reset the epigenetic and transcriptional state of fibroblasts into that of pluripotent cells ([@b28-gmb-35-3-693]). This technology provides alternative pluripotent cells that closely resemble blastocyst-derived embryonic stem cells (ESCs), which are considered the gold standard for stem cells ([@b28-gmb-35-3-693]; [@b20-gmb-35-3-693]). The replacement of ESCs with iPSCs in the field of regenerative medicine is based on the assumption that iPSCs are as potent as ESCs in their ability to differentiate and in their safety for clinical applications ([@b5-gmb-35-3-693]). Mouse iPSCs have the same functional characteristics as mouse ESCs, as shown by their capacity to generate mice in tetraploid complementation experiments ([@b4-gmb-35-3-693]; [@b19-gmb-35-3-693]; [@b33-gmb-35-3-693]). In contrast, this convincing pluripotency test is difficult to execute in human iPSCs (hiPSCs). Genome-wide profiling analysis of gene expression ([@b8-gmb-35-3-693]), DNA methylation patterns ([@b7-gmb-35-3-693]) and differentiation properties have detected incomplete reprogramming in hiPSCs. These findings suggest that there are substantial differences between hESCs and hiPSCs.

The advantages and disadvantages of the delivery method for each factor have been discussed elsewhere ([@b1-gmb-35-3-693]; [@b9-gmb-35-3-693]). Since the first report on iPSCs produced by retroviral delivery of four factors (OSKM), a substantial number of alternative approaches have been developed to induce pluripotency. In this report, we describe a meta-analysis of gene expression information from multiple independent but related studies (summarized in [Table 1](#t1-gmb-35-3-693){ref-type="table"}). For this, we compared the transcription signatures of hiPSCs generated by different methods and transcriptional factors, with hESCs serving as the gold standard. We also determined the detailed molecular events involved in human cell reprogramming by comparing the transcriptomes of hiPSCs and fibroblasts.

Materials and Methods
=====================

Source of gene expression data
------------------------------

All of the microarray information and individual cell intensity (CEL) files in the HG-U133Plus2 microarray platform (Affymetrix) were obtained online at the Gene Expression Omnibus (GEO), a public repository for a wide range of high-throughput experimental data. The donor cells and different hiPSC lines are summarized in [Table 1](#t1-gmb-35-3-693){ref-type="table"}.

Microarray analysis
-------------------

We imported datasets from GEO into GeneSpring GX 11.0 using a guided workflow step to identify potential targets that were both statistically and biologically meaningful. Probe sets with gene-level normalized intensities greater than log (base 2) of 5.0 in a least one sample were excluded from ANOVA. The data were then filtered based on their flag values (P -- present and A -- absent) to remove probe sets for which the signal intensities for all the treatment groups were in the lowest 20 percentile of all intensity values. ANOVA in conjunction with the Benjamini-Hochberg FDR multiple test correction was used to identify genes that were differentially expressed between different groups. The level of significance was set at p \< 0.05.

Gene ontology (GO) annotation and pathway analysis
--------------------------------------------------

The functions of up- or down-regulated genes in iPSCs *vs.* somatic cells were investigated by using the Database for Annotation, Visualization and Integrated Discovery (DAVID) v 6.7 ([@b15-gmb-35-3-693]) based on gene ontology (GO) ([@b3-gmb-35-3-693]) annotations. In addition, groups of genes associated with specific pathways (based on the Kyoto Encyclopedia of Genes and Genomes -- KEGG) were analyzed together to assess pathway regulation during reprogramming.

Network analysis
----------------

We investigated the possible functional associations between the top 484 noticeably significant unregulated genes in iPSCs compared with fibroblasts using the STRING database (STRING score of at least 0.5) ([@b29-gmb-35-3-693]). Gene networks for which there was high confidence as interacting partners were visualized using MEDUSA ([@b14-gmb-35-3-693]).

Results
=======

Comparative global transcriptomic analysis of iPSCs and ESCs
------------------------------------------------------------

[Figure 1](#f1-gmb-35-3-693){ref-type="fig"} provides a flowchart of the global transcriptomic analysis. Reprogramming methods can be divided into two classes, *i.e.*, those that are integration-free (including synthetic modified mRNA, episomes, proteins and minicircles) and those involving the integration of exogenous transcription factors (lentiviral and retroviral methods and inducible reprogramming systems). Most (75%) of the iPSCs analyzed in this study used fibroblasts as the donor cell type. ANOVA was used to determine the degree of reprogramming within hiPSCs derived using different methods of induction and transcription factors, and to examine the "distance", *i.e.*, number of differentially expressed genes (based on cut-off criteria of p \< 0.05 and a fold-change = 2), among hESCs, hiPSCs and their corresponding donor cells ([Figure 1](#f1-gmb-35-3-693){ref-type="fig"}). To eliminate the influence of micro-environmental factors associated with different laboratories and the genetic background of donor cells, the differentially expressed genes were identified by comparing iPSCs and ESCs derived from the same laboratory and donor animals of the same sex ([Table 1](#t1-gmb-35-3-693){ref-type="table"}). [Table S1 (Supplementary material)](#SD1){ref-type="supplementary-material"} provides a detailed list of the genes that were differentially expressed between iPSCs and ESCs.

We also analyzed the relationship between the "distance" of iPSCs *vs.* ESCs and the method used to deliver the transcription factor(s). iPSCs generated by integrating viral vectors (moloney-based retrovirus and HIV-based lentivirus) were not as close to ESC lines as iPSCs generated by non-integrating methods (episomes, synthetic modified mRNA, proteins and minicircle DNA) ([Figure 2A](#f2-gmb-35-3-693){ref-type="fig"}). The type of transcription factor used had little impact on the gene expression signature of iPSCs ([Figure 2B](#f2-gmb-35-3-693){ref-type="fig"}). No overlapping genes were differentially expressed between hESCs and hiPSCs derived from various reprogramming experiments, *i.e.*, there were no consistent differences in the global gene expression between human ESCs and iPSCs. These findings supported the idea that reprogramming progressed through a series of stochastic events to produce pluripotency.

Functional analysis of significantly altered genes between iPSCs and donor cells
--------------------------------------------------------------------------------

The detailed molecular events involved in reprogramming to produce iPSCs remain largely unknown. To address this issue, we undertook an in-depth analysis of the biological functions of differentially expressed genes in all 20 iPSC lines *vs.* donor fibroblasts; the selection criteria were again p \< 0.05 (Student's *t*-test) and at least a two-fold difference in gene expression. [Table 1](#t1-gmb-35-3-693){ref-type="table"} summarizes the number of differentially expressed genes between the iPSC lines and the original cell lines. Of these, 312 genes up-regulated in each iPSC line were compared with fibroblasts ([Table S2](#SD2){ref-type="supplementary-material"}). We defined the 312 up-regulated probes as essential for maintaining the pluripotency of hiPSCs (EMP genes). The STRING database was used to visualize all known functional interactions between EMP genes in iPSC lines using the default cutoff suggested by STRING. One hundred and fifty-nine genes in this set (32%) interacted with each other ([Figure 3](#f3-gmb-35-3-693){ref-type="fig"}). The functional network of genes with higher expression levels in iPSCs showed a central, highly interconnected area in which common pluripotency regulators such as Pou5f1, Nanog, Lin28, Dnmt3 and Dppa4 were identified. This finding indicated that hiPSCs and hESCs shared a similar core network to maintain pluripotency. The absence of Sox2 in this analysis reflects the fact that [@b24-gmb-35-3-693] used mouse neural stem cells (NSCs), which have a high endogenous expression of Sox2, as the donor cell lines to induce reprogramming. Hence, Sox2 was not included in the 312 genes unregulated in iPSCs. This protein interaction network for pluripotency provides a model for exploring neo-factors that may enhance the induction of reprogramming.

We took advantage of a recently published microarray dataset ([@b31-gmb-35-3-693]) to study the dynamic changes in EMP genes during mammalian preimplantation embryonic development ([Table S3](#SD3){ref-type="supplementary-material"}). One hundred and twenty EMP genes, including Pou5f1 Dppa4 and Lin28, were up regulated during the transitional phase from the four-cell stage to the eight-cell stage of human early embryonic development, known as the human zygotic genome activation period ([@b13-gmb-35-3-693]) ([Figure 4](#f4-gmb-35-3-693){ref-type="fig"}). This pluripotent network, which is essential for maintaining the self-renewal of iPSCs, also plays a pivotal role in establishing embryos *in vivo*. The 101 EMP genes that were down-regulated during the process could contribute to the differentiation of stem cells *in vivo* and *in vitro*.

The functions associated with genes that were significantly altered in reprogramming were examined by analyzing the over-represented annotations and pathways using DAVID, with a cut-off criterion of p \< 0.01. The over-represented GO terms focused on "regulation of transcription" and "regulation of cell proliferation" ([Table S4](#SD4){ref-type="supplementary-material"}). The results of this analysis supported the idea that an increase in proliferation rate was necessary for fully cellular reprogramming ([@b27-gmb-35-3-693]).

We also analyzed whether significant pathways in iPSCs were enriched in significantly altered genes. The results showed that hiPSCs were responsive to the TGF-β signaling pathway that regulates the maintenance of pluripotency, self-renewal and proliferation of hESCs ([Table S4](#SD4){ref-type="supplementary-material"}). These results demonstrated that hiPSCs reprogrammed from somatic or embryonic cells relied on similar signaling pathways to control their pluripotency.

Discussion
==========

The results described herein show that the overall transcriptional profiles of different human iPSC lines shared a common "signature" with hESCs, although there were certain differences. Notably, the transcriptomes of hiPSCs produced by a delivery method that avoided genomic integration shared a greater gene expression signature with hESCs than did iPSCs produced by a virus-based method. Gene-delivery methods can affect the quality of the resulting iPSCs by influencing the amount, balance, continuity and silencing of transgene expression. Potent oncogenes such as *myc* apparently have little effect on the transcriptional signature of iPSCs. Our findings provide a basis for selecting the most suitable method for clinical or basic applications and a better understanding of the reprogramming process.

This study also improves our understanding of the mechanisms of cellular reprogramming. The transcriptional network maintains the self-renewal and pluripotency of iPSCs established primarily during preimplantation at the stage of zygote genome activation. Detailed analysis showed that increased proliferation and the up-regulation of genes that drive the cell cycle are necessary events for fibroblast reprogramming. Recent reports have shown that hiPSCs are more tumorigenic than hESCs based on a comparison of protein-coding point mutations ([@b10-gmb-35-3-693]), copy number variations ([@b16-gmb-35-3-693]) and DNA methylation ([@b22-gmb-35-3-693]). Together, these results stress the link between pluripotency and tumorigenicity. Given that self-renewal is a hallmark of ESCs and cancer cells, the ability to induce tumors during cellular reprogramming implies that there are potential risks involved in the use of iPSCs for regenerative therapy.

In addition, non-coding RNA, including microRNA (miRNA) and large intergenic non-coding (lincRNA), which may represent a distinct layer to fine-tune the transcriptional network of stem cells, has a role in modulating the induction of reprogramming ([@b18-gmb-35-3-693]; [@b23-gmb-35-3-693]). Significantly, recent work has shown that a single miRNA cluster rapidly reprogrammed mouse and human fibroblasts into iPSCs and totally avoided the use of transcription factors ([@b2-gmb-35-3-693]). The mechanism underlying reprogramming by miRNA differs from that of transcription factor-induced reprogramming in that there is no requirement for protein translation; the former method also targets hundreds of ESC-related mRNAs directly.

In conclusion, we have examined the gene expression profiles of iPSCs obtained by different methods and from donor cell of different of origins. iPSCs produced by non-integrative methods are more closely resembled the fully reprogrammed pluripotent state than did iPSCs obtained by using integrative delivery systems, although the efficiency and kinetics were lower. Some of the results described here may reflect the markedly different circumstances in which they were generated, *e.g.*, the culture conditions, the passage number at which the cells were used and the age of the donor cells. Another limitation in our analysis was that only the initial state (donor cell) and end state (pluripotent cell) of reprogramming were examined.

Further research on each aspect of reprogramming, *e.g.*, the initial transcriptional response to the induction of reprogramming, the epigenetic roadblocks, the partially pluripotent state and the late events leading to pluripotency, is required in order to understand how reprogramming leads to pluripotency. A comprehensive understanding of the events involved in reprogramming a set of iPSCs can only be reached by examining the changes in the corresponding transcriptome (protein coding RNA, microRNA and lincRNA expression), epigenome (genome imprint, X chromosome activation, histone modifications and DNA methylation), metabolome and proteome.
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Supplementary Material
======================

The following online material is available for this article:

Table S1 - Genes differentially expressed between iPSC lines and their original donor cells.

Table S2 -- A detailed list of genes dynamically expressed during early embryonic development.

Table S3 - The over-represented classification of GO annotations for differentially expressed genes in iPSCs and ESCs compared with donor cells.

Table S4 - The over-represented classification of pathways for 1942 differentially expressed genes in iPSCs compared with donor cells.

This material is available as part of the online article from <http://www.scielo.br/gmb>.

![A schematic overview of the approach used in this study. The microarray data for ESCs, iPSCs and their donor cells were obtained from the GEO database. Comparison of the gene expression signature between ESCs and iPSCs showed that the characteristics of the reprogramming varied according to the strategy used. Likewise, comparison of the gene expression signature between iPSCs and original donor cells provided insights into the process of induced reprogramming.](gmb-35-3-693-gfig1){#f1-gmb-35-3-693}

![The transcriptional signature of iPSCs from different laboratories using different methods of induction and different transcription factors. (A) iPSCs generated by integrating viral vectors were less closely related to ESCs than iPSCs generated by a non-integrating method. (B) The choice of transcription factor (OS, OSK, OSNL, OSKMN and OSKM) did not significantly affect the transcriptional profile of iPSCs. K: Klf4, L: Lin28, M: c-Myc, N: Nanog, O: Oct4, S: Sox2. \*p \< 0.05 and \*\*p \< 0.001 compared to the retroviral method.](gmb-35-3-693-gfig2){#f2-gmb-35-3-693}

![Predicted stem-cell-specific protein-protein interaction network of genes with higher expression levels in iPSCs compared to somatic cells.](gmb-35-3-693-gfig3){#f3-gmb-35-3-693}

![The gene expression tendency of 312 transcripts (EMP genes) in different stages of human preimplantation embryonic development. One hundred and twenty transcripts were upregulated and 101 transcripts were down-regulated, the later mainly in the four-cell stage to eight-cell stage. Red represents the up regulated expressed genes and green the down-regulated ones.](gmb-35-3-693-gfig4){#f4-gmb-35-3-693}

###### 

Data for 20 hiPSC lines derived from cells of different origins and different methods of induction. The dataset for each iPSC line includes the donor cells, method of induction and reprogramming factors. The differentially expressed genes were identified by comparing iPSCs and ESCs of the same sex and from the same laboratory. All of the microarray data can be retrieved through the corresponding GEO number. *iPSCs-ESCs* indicates the number of differentially expressed genes between iPSCs and ESCs, and *iPSCs-fibroblasts* indicates the number of differentially expressed genes between iPSCs and fibroblasts. K: Klf4, L: Lin28, M: c-Myc, N: Nanog, O: Oct4, S: Sox2.

  Donor cells       iPSCs                   Method of induction   Reprogramming factors   ESCs               Sex   GEO number   iPSCs-ESCs   iPSCs-fibroblasts   Reference
  ----------------- ----------------------- --------------------- ----------------------- ------------------ ----- ------------ ------------ ------------------- ---------------------
  NPC               iPS 462813              Episome               OS                      HUES6              F     GSE18618     9507         7688                [@b24-gmb-35-3-693]
  MSC fibroblasts   MSC-derived iPSC line   Retroviral            OSKM                    BG01 ESCs          M                  1424         15106               [@b24-gmb-35-3-693]
  Foreskin          iPS cells               Episome               OSNL                    H13B ESC           M     GSE15148     8823         9689                [@b32-gmb-35-3-693]
  Foreskin          JT-iPSC                 Episome               OSNL                    H13                M     GSE20014     1843         10673               [@b17-gmb-35-3-693]
  Foreskin          iPSC                    Minicircle DNA        OSNL                    H13                M                  7668         12092               [@b17-gmb-35-3-693]
  Fibroblast        hiPSC                   Retroviral            OSKMN                   Hsf1 p51           F     GSE22392     10048        9598                [@b6-gmb-35-3-693]
  Fibroblast        hiPS                    Inducible system      OSK                     hES_BG01           M     GSE22499     6209         15684               [@b12-gmb-35-3-693]
  Fibroblast        hiPSC                   Proteins              OSKMN                   H9 hESCs           F     GSE16093     1610         9104                [@b21-gmb-35-3-693]
  dH1f fibroblast   dH1f-iPS3               Retroviral            OSKM                    H1-OGN hES cells   M     GSE9832      8658         8614                [@b26-gmb-35-3-693]
  dH1cf16           dH1cf16-iPS5            Retroviral            OSKM                    H1-OGN hES cells   M                  11159        7793                [@b26-gmb-35-3-693]
  BJ fibroblast     BJ_iPS                  Retroviral            OSKM                    H1_ES-1            M                  14523        15424               [@b26-gmb-35-3-693]
  dH1F fibroblast   dH1F_iPS3               Retroviral            OSKM                    H1_ES-1            M     GSE23583     8658         15243               [@b30-gmb-35-3-693]
  dH1F fibroblast   dH1F_RiPS               mRNA                  OSKM                    H1_ES-1            M                  9125         11490               [@b30-gmb-35-3-693]
  BJ1 fibroblast    BJ1-iPSC 2              Retroviral            OSKM                    BG01 ESCs          M                  2188         12499               [@b30-gmb-35-3-693]
  BJ fibroblast     BJ_RiPS                 mRNA                  OSKM                    H1_ES-1            M                  10173        11072               [@b30-gmb-35-3-693]
  MRC5 fibroblast   MRC5_RiPS               mRNA                  OSKM                    H1_ES-1            M                  10445        12092               [@b30-gmb-35-3-693]
  BJ1 fibroblast    BJ1-iPS1                Retroviral            OSKM                    H1-OGN hES cells   M     GSE24182     2920         15424               [@b23-gmb-35-3-693]
  CB_CD133+         CBiPS_4F                Retroviral            OSKM                    ES2_1              F     GSE16694     15414        16810               [@b11-gmb-35-3-693]
  CB_CD133+         CBiPS_2F                Retroviral            OS                      ES2_1              F                  14523        8614                [@b26-gmb-35-3-693]
  BJ sample         BJ hIPS                 Inducible system      OSKMN                   HUES 8 p           M     GSE12390     6159         15684               [@b25-gmb-35-3-693]
